Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
CGRP
Eptinezumab
MBS
Migraine
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
03 Jun 2022
03 Jun 2022
Historique:
received:
01
02
2022
accepted:
11
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including nausea, photophobia, or phonophobia) compared with placebo when administered during a migraine attack. The objective of this exploratory analysis was to examine the earliest time points that eptinezumab separated from placebo (P < .05) on headache- and migraine-associated symptoms when administered during a migraine attack. RELIEF, a multicenter, parallel-group, double-blind trial, occurred from November 7, 2019, through July 8, 2020. Adults considered candidates for preventive treatment were randomized to eptinezumab 100 mg (N = 238) or placebo (N = 242) administered intravenously over 30 min within 1-6 h of migraine onset. Outcome measures included headache pain freedom/relief and absence of MBS, patient's choice of photophobia, phonophobia, or nausea, at regular intervals from 0.5 to 48 h after infusion start. Censoring was applied at time of acute rescue medication use. At hour 1, more eptinezumab-treated patients achieved headache pain freedom (9.7%), headache pain relief (38.7%), and absence of MBS (33.2%) versus placebo (4.1%, 26.9%, and 22.1%, respectively; P < .05 all), with separation from placebo (P < .05) through hour 48. Eptinezumab separated from placebo (P < .05) at hour 1 in absence-of-photophobia (29.4% vs 17.0%) and absence-of-phonophobia (41.2% vs 27.2%) and through hour 48. Initial separation from placebo (P < .05) in absence-of-nausea occurred at end-of-infusion (0.5 h; 36.7% vs 25.4%, respectively). Preventive treatment with eptinezumab initiated during a migraine attack resulted in more patients achieving headache pain freedom/relief and absence of MBS, with separation from placebo (P < .05) as early as 0.5-1 h following the start of infusion. Rapid resolution of headache- and migraine-associated symptoms by a peripherally acting, intravenously administered antibody suggest a peripheral site of pharmacological action for CGRP blockade. ClinicalTrials.gov Identifier: NCT04152083 .
Sections du résumé
BACKGROUND
BACKGROUND
Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including nausea, photophobia, or phonophobia) compared with placebo when administered during a migraine attack. The objective of this exploratory analysis was to examine the earliest time points that eptinezumab separated from placebo (P < .05) on headache- and migraine-associated symptoms when administered during a migraine attack.
METHODS
METHODS
RELIEF, a multicenter, parallel-group, double-blind trial, occurred from November 7, 2019, through July 8, 2020. Adults considered candidates for preventive treatment were randomized to eptinezumab 100 mg (N = 238) or placebo (N = 242) administered intravenously over 30 min within 1-6 h of migraine onset. Outcome measures included headache pain freedom/relief and absence of MBS, patient's choice of photophobia, phonophobia, or nausea, at regular intervals from 0.5 to 48 h after infusion start. Censoring was applied at time of acute rescue medication use.
RESULTS
RESULTS
At hour 1, more eptinezumab-treated patients achieved headache pain freedom (9.7%), headache pain relief (38.7%), and absence of MBS (33.2%) versus placebo (4.1%, 26.9%, and 22.1%, respectively; P < .05 all), with separation from placebo (P < .05) through hour 48. Eptinezumab separated from placebo (P < .05) at hour 1 in absence-of-photophobia (29.4% vs 17.0%) and absence-of-phonophobia (41.2% vs 27.2%) and through hour 48. Initial separation from placebo (P < .05) in absence-of-nausea occurred at end-of-infusion (0.5 h; 36.7% vs 25.4%, respectively).
CONCLUSION
CONCLUSIONS
Preventive treatment with eptinezumab initiated during a migraine attack resulted in more patients achieving headache pain freedom/relief and absence of MBS, with separation from placebo (P < .05) as early as 0.5-1 h following the start of infusion. Rapid resolution of headache- and migraine-associated symptoms by a peripherally acting, intravenously administered antibody suggest a peripheral site of pharmacological action for CGRP blockade.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT04152083 .
Identifiants
pubmed: 35659622
doi: 10.1186/s12883-022-02714-1
pii: 10.1186/s12883-022-02714-1
pmc: PMC9164335
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
eptinezumab
8202AY8I7H
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Banques de données
ClinicalTrials.gov
['NCT04152083']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–76. https://doi.org/10.1016/s1474-4422(18)30322-3 .
doi: 10.1016/s1474-4422(18)30322-3
Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW, et al. Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study. Headache. 2020;60(2):416–29. https://doi.org/10.1111/head.13708 .
doi: 10.1111/head.13708
pubmed: 31837007
Garcia-Martinez LF, Raport CJ, Ojala EW, Dutzar B, Anderson K, Stewart E, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. JPET. 2020;374(1):93–103. https://doi.org/10.1124/jpet.119.264671 .
doi: 10.1124/jpet.119.264671
VYEPTI [package insert]. In. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2021.
Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–9. https://doi.org/10.1016/j.phrs.2016.07.015 .
doi: 10.1016/j.phrs.2016.07.015
pubmed: 27438459
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on Day 1 after dosing. Headache. 2020;60(10):2220–31. https://doi.org/10.1111/head.14007 .
doi: 10.1111/head.14007
pubmed: 33165938
pmcid: 7756794
Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348–56. https://doi.org/10.1001/jama.2021.7665 .
doi: 10.1001/jama.2021.7665
pubmed: 34128999
Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–54. https://doi.org/10.1177/0333102420905132 .
doi: 10.1177/0333102420905132
pubmed: 32075406
pmcid: 7066477
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology. 2020;94(13):e1365–77. https://doi.org/10.1212/WNL.0000000000009169 .
Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6(6):534–47. https://doi.org/10.1002/cpdd.345 .
doi: 10.1002/cpdd.345
pubmed: 28409893
pmcid: 5697612
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202 .
doi: 10.1177/0333102417738202
FDA. Migraine: Developing Drugs for Acute Treatment Guidance for Industry. 2018. ( https://www.fda.gov/media/89829/download Accessed 8/4/2021).
Diener H-C, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019;39(6):687–710. https://doi.org/10.1177/0333102419828967 .
doi: 10.1177/0333102419828967
pubmed: 30806518
pmcid: 6501455
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–41. https://doi.org/10.1056/NEJMoa1813049 .
doi: 10.1056/NEJMoa1813049
pubmed: 31800988
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98. https://doi.org/10.1001/jama.2019.16711 .
doi: 10.1001/jama.2019.16711
pubmed: 31742631
pmcid: 6865323
Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, Adams AM, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia. 2021;41(5):546–60. https://doi.org/10.1177/0333102420970523 .
doi: 10.1177/0333102420970523
pubmed: 33241721
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene–related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9. https://doi.org/10.1056/NEJMoa1811090 .
doi: 10.1056/NEJMoa1811090
pubmed: 31291516
Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine-a PET study. J Headache Pain. 2014;15(1):84. https://doi.org/10.1186/1129-2377-15-84 .
doi: 10.1186/1129-2377-15-84
pubmed: 25471540
pmcid: 4266549